Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8)

Authors not listed

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2000

Abstract

The long-term safety and efficacy of galantamine (12 mg bid) will be documented during a one year open-label treatment in subjects with Alzheimer's Disease who completed the GAL-INT-8 trial (up to 400 eligible patients). Safety will be tracked by means of adverse event reports, laboratory parameters and physical exam. Long-term efficacy will be evaluated by means of a Alzheimer's Disease Assessment Scale(ADAS) and activities of daily living scale Disability Assessment for Dementia Scale(DAD)

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Anonymous. (2000). Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8). <em>Johnson & Johnson Pharmaceutical Research & Development, L.L.C.</em>. https://clinicaltrials.gov/study/NCT00304629
Vancouver
Anonymous. Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8). Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 2000.
BibTeX
@misc{anon2000LongTe, title = {Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8)}, author = {Anonymous}, journal = {Johnson & Johnson Pharmaceutical Research & Development, L.L.C.}, year = {2000}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings